Endospan, a pioneer in endovascular solutions for complex aortic pathologies, announced on Monday that it has been acquired by medical device company Artivion Inc (NYSE: AORT) following US Food and Drug Administration premarket approval of the NEXUS Aortic Arch System, marking a strategic expansion in endovascular aortic repair technologies.

This transaction, valued at USD175m less offsets for prior loans, includes up to a further USD200m in contingent consideration based on US commercial performance over the next two years. The deal strengthens Artivion's position in advanced aortic disease treatment, particularly in minimally invasive endovascular solutions.

The NEXUS system is the first off-the-shelf endovascular device designed to treat complex aortic arch disease, including chronic aortic dissections, in high-risk patients unsuitable for open surgery. It will be integrated into Artivion's global cardiovascular portfolio spanning stent grafts, surgical sealants, mechanical heart valves and implantable tissues.

Artivion said Endospan's technology is already established in international markets, with the company serving as exclusive distributor of the NEXUS system across EMEA since 2019. The acquisition is expected to support broader commercial rollout across Europe, Asia-Pacific and Latin America while advancing US launch plans.

Endospan, headquartered in Israel, has developed multiple configurations of its NEXUS platform for complex anatomical cases.